

Human 4-1BB Ligand/TNFSF9 APC-conjugated Antibody Monoclonal Mouse IgG_{2B} Clone # 282220

Catalog Number: FAB2295A

100 TESTS


DESCRIPTION			
Species Reactivity	y Human		
Specificity	Detects human 4-1BB Ligand/TNFSF9 in direct ELISAs and Western blots. In Western blots, no cross-reactivity with recombinant mous 4-1BB Ligand, recombinant human (rh) APRIL, rhBAFF, rmEDA-A2, rhFas Ligand, rhGITR Ligand, rhLIGHT, rhLymphotoxin α1/β2, rhLymphotoxin α2/β1, rhOX40 Ligand, rhTNF-α, rhTRAIL, rhTRANCE, or rhTWEAK is observed.		
Source	Monoclonal Mouse IgG _{2B} Clone # 282220		
Purification	Protein A or G purified from hybridoma culture supernatant		
Immunogen	E. coli-derived recombinant human 4-1BB Ligand/TNFSF9 Arg71-Glu254 Accession # P41273.1		
Conjugate	Allophycocyanin Excitation Wavelength: 620-650 nm Emission Wavelength: 660-670 nm		
Formulation	Supplied in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details.		
	*Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.		

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Flow Cytometry	10 μL/10 ⁶ cells	See Below

DATA



Detection of 4-1BB Ligand/TNFSF9 in Daudi Human Cell Line by Flow Cytometry. Daudi human Burkitt's lymphoma cell line was stained with Mouse Anti-Human 4-1BB Ligand/TNFSF9 APC-conjugated Monoclonal Antibody (Catalog # FAB2295A, filled histogram) or isotype control antibody (Catalog # IC0041A, open histogram). View our protocol for Staining Membraneassociated Proteins.

PREPARATION AND STORAGE

Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Protect from light. Do not freeze.

12 months from date of receipt, 2 to 8 °C as supplied.





Human 4-1BB Ligand/TNFSF9 APC-conjugated Antibody

Monoclonal Mouse IgG_{2B} Clone # 282220

Catalog Number: FAB2295A

100 TESTS

BACKGROUND

4-1BB Ligand (4-1BBL; also TNFSF9 and CD137L) is a 32 kDa type II transmembrane protein that belongs to the TNF superfamily (TNFSF) molecules (1-4). The human 4-1BBL cDNA encodes a 254 amino acid (aa) protein that contains a 25 aa N-terminal cytoplasmic domain, a 23 aa transmembrane segment, and a 206 aa C-terminal extracellular region (5). The extracellular domain (ECD) of 4-1BBL has a jelly-roll, β-sandwich tertiary structure that is similar to other TNFSF members. There is only one cysteine in the human ECD, and no potential N-linked glycosylation sites. The potential exists, however, for O-linked glycosylation. The human 4-1BBL ECD shares 32% and 35% aa identity with mouse and rat ECD, respectively. In the cytoplasmic domain, human 4-1BBL is 55 aa shorter than the equivalent region in rodents. 4-1BBL is expressed by activated B cells, macrophages, dendritic cells, activated T cells, neurons and astrocytes (2, 3, 6). A bioactive 26 kDa soluble form of 4-1BBL, presumably generated by MMP cleavage, occurs in humans (4). Human 4-1BBL signals through both CD137/4-1BB and itself. Its cytoplasmic tail participates in reverse signaling that induces apoptosis in T cells and cytokine secretion (IL-6; TNF-α) by monocytes (7, 8). 4-1BBL binding to CD137/4-1BB produces a number of effects. It seems to play a key role in the T cell recall response. It maintains T cell numbers at the end of a primary response, and induces CD4⁺ and CD8⁺ T cells to proliferate and secrete cytokines such as IL-2 and IFN-γ in CD4⁺ cells, and IFN-γ in CD8⁺ cells (9, 10).

References:

- 1. Kwon, B. et al. (2003) Exp. Mol. Med. 35:8.
- 2. Salih, H.R. et al. (2002) Int. J. Clin. Pharmacol. Ther. 40:348.
- 3. Vinay, D.S. and B.S. Kwon (1998) Semin. Immunol. 1:481.
- 4. Salih, H.R. et al. (2001) J. Immunol. 167:4059.
- 5. Alderson, M.R. et al. (1994) Eur. J. Immunol. 24:2219.
- 6. Reali, C. et al. (2003) J. Neurosci. Res. 74:67.
- 7. Michel, J. et al. (1999) Immunology 98:42.
- 8. Langstein, J. et al. (1998) J. Immunol. 160:2488.
- 9. Wen, T. et al. (2002) J. Immunol. 168:4897.
- 10. Dawicki, W. and T.H. Watts (2004) Eur. J. Immunol. 34:743.

